Announced details
Aging, healthy life expectancy, age-related diseases, immunity, metabolism, bones and muscles, cognition and neurophysiology, oxidative stress, hematopoietic stem cells
Biological age was reduced by 3.4 years under the Horvath method and by 1.9 years under the PC-Horvath method. After 4 months of dosing, reductions were observed in 15 of 19 participants under the Horvath method and in 18 of 19 participants under the PC-Horvath method.
20 patients dosed in the semifinal clinical trial (the subjects of the safety evaluation in this trial)
The clinical trial was conducted jointly with Tohoku University Hospital, Hiroshima University and Tokai University. The relationship with the XPRIZE Foundation involves submitting an application to the competition and submitting materials to the evaluation committee.
Tohoku University Hospital, Hiroshima University and Tokai University served as collaborating institutions for conducting the trial and performing testing. The XPRIZE Foundation organizes XPRIZE Healthspan. Other information, including location, representative, capital and year of establishment, is not disclosed.
XPRIZE Healthspan semifinalist (TOP40)
XPRIZE Foundation
20 participants; 19 participants evaluated for efficacy and 20 participants evaluated for safety after dosing with RS5614
There is currently no particular impact on results for the fiscal year ending March 2027.
The company does not address Contract Value / Offering price.
XPRIZE Healthspan call for applications; Horvath method and PC-Horvath method; SomaScan assay
| Item | Details |
|---|---|
| Names of Products / Services Covered | PAI-1 inhibitor RS5614; XPRIZE Healthspan semifinal clinical trial |
| Counterparty | Tohoku University Hospital, Hiroshima University, Tokai University, XPRIZE Foundation |
| Counterparty overview | Tohoku University Hospital, Hiroshima University and Tokai University served as collaborating institutions for conducting the trial and performing testing. The XPRIZE Foundation organizes XPRIZE Healthspan. Other information, including location, representative, capital and year of establishment, is not disclosed. |
| Relationship with the Company | The clinical trial was conducted jointly with Tohoku University Hospital, Hiroshima University and Tokai University. The relationship with the XPRIZE Foundation involves submitting an application to the competition and submitting materials to the evaluation committee. |
| Launch date | August 2025 (start of the semifinal clinical trial; actual) |
| Applicable area | Aging, healthy life expectancy, age-related diseases, immunity, metabolism, bones and muscles, cognition and neurophysiology, oxidative stress, hematopoietic stem cells |
| Award/certification name | XPRIZE Healthspan semifinalist (TOP40) |
| Awarding / certifying body | XPRIZE Foundation |
| Location scale | 20 participants; 19 participants evaluated for efficacy and 20 participants evaluated for safety after dosing with RS5614 |
| Quantitative Effects | Biological age was reduced by 3.4 years under the Horvath method and by 1.9 years under the PC-Horvath method. After 4 months of dosing, reductions were observed in 15 of 19 participants under the Horvath method and in 18 of 19 participants under the PC-Horvath method. |
| Usage history | 20 patients dosed in the semifinal clinical trial (the subjects of the safety evaluation in this trial) |
| Impact on Business Performance | There is currently no particular impact on results for the fiscal year ending March 2027. |
| Source | XPRIZE Healthspan call for applications; Horvath method and PC-Horvath method; SomaScan assay |
Items this document does not state (5)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The semifinal clinical trial was completed and preliminary results became available.